{
    "__type__": "Deck",
    "children": [],
    "crowdanki_uuid": "67fd1346-79b1-11ec-a1eb-f45c899656dd",
    "deck_config_uuid": "2fcf2790-769e-11ec-baf6-f45c899656dd",
    "deck_configurations": [
        {
            "__type__": "DeckConfig",
            "autoplay": true,
            "crowdanki_uuid": "2fcf2790-769e-11ec-baf6-f45c899656dd",
            "dyn": false,
            "interdayLearningMix": 0,
            "lapse": {
                "delays": [
                    10.0
                ],
                "leechAction": 0,
                "leechFails": 8,
                "minInt": 1,
                "mult": 0.0
            },
            "maxTaken": 60,
            "name": "Default",
            "new": {
                "bury": false,
                "delays": [
                    1.0,
                    10.0
                ],
                "initialFactor": 2500,
                "ints": [
                    1,
                    1,
                    0
                ],
                "order": 1,
                "perDay": 600
            },
            "newGatherPriority": 0,
            "newMix": 0,
            "newPerDayMinimum": 0,
            "newSortOrder": 0,
            "replayq": true,
            "rev": {
                "bury": false,
                "ease4": 1.3,
                "hardFactor": 1.2,
                "ivlFct": 1.0,
                "maxIvl": 36500,
                "perDay": 200
            },
            "reviewOrder": 0,
            "timer": 0
        }
    ],
    "desc": "",
    "dyn": 0,
    "extendNew": 0,
    "extendRev": 0,
    "media_files": [
        "paste-06b2914e3c5d990893caa4f38632125072211bab.jpg",
        "paste-69274b465dcda3b05d6ecd4bfb8afc1be486f880.jpg"
    ],
    "name": "MSBS::MBM II::Block 1::Week 3",
    "note_models": [
        {
            "__type__": "NoteModel",
            "crowdanki_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "css": ".card {\n font-family: arial;\n font-size: 20px;\n text-align: center;\n color: black;\n background-color: white;\n}\n\n/* TAGS */\n/* Container To Fix Tags At Bottom Of Screen */\n#tags-container{\nposition: fixed;\nbottom: .5px;\npadding-bottom: 0px;\nwidth: 100%;\nline-height: .45rem;\nmargin-left: -15px;\n}\n\n/* Clickable Tags (need to download the add-on) */\nkbd {\n display: inline-block;\n letter-spacing: .2px;\n font-weight: bold;\n font-size: 12px !important;\n text-shadow: none !important;\n padding: 0.05rem 0.1rem !important;\n margin: 1px -3px !important;\n border-radius: 4px;\n border-width: 1.5px !important;\n border-style: solid;\n background-color: transparent !important;\n box-shadow: none !important;\n opacity: 0.5;\n vertical-align: middle;\n}\n\n/* Tag Becomes More Visible On Hover */\nkbd:hover { opacity: 1; transition: opacity 0.2s ease; }\n\n/* Tag Colors */\nkbd:nth-of-type(1n+0) { border-color: #F44336; color: #F44336; }\nkbd:nth-of-type(2n+0) { border-color: #9C27B0; color: #9C27B0; }\nkbd:nth-of-type(3n+0) { border-color: #3F51B5; color: #3F51B5; }\nkbd:nth-of-type(4n+0) { border-color: #03A9F4; color: #03A9F4; }\nkbd:nth-of-type(5n+0) { border-color: #009688; color: #009688; }\nkbd:nth-of-type(6n+0) { border-color: #C0CA33; color: #C0CA33; }\nkbd:nth-of-type(7n+0) { border-color: #FF9800; color: #FF9800}\nkbd:nth-of-type(8n+0) { border-color: #FF5722; color: #FF5722; }\nkbd:nth-of-type(9n+0) { border-color: #9E9E9E; color: #9E9E9E; }\nkbd:nth-of-type(10n+0) { border-color: #607D8B; color: #607D8B; }\n\n/* Tag Mobile Adjustments */\n.mobile kbd { opacity: .9; margin: 1px !important; display: inline-block; font-size: 10px !important; }\n.mobile #tags-container {line-height:0.6rem; margin-left: 0px; }\n",
            "flds": [
                {
                    "font": "Arial",
                    "media": [],
                    "name": "Front",
                    "ord": 0,
                    "rtl": false,
                    "size": 20,
                    "sticky": false
                },
                {
                    "font": "Arial",
                    "media": [],
                    "name": "Back",
                    "ord": 1,
                    "rtl": false,
                    "size": 20,
                    "sticky": false
                },
                {
                    "font": "Arial",
                    "media": [],
                    "name": "Big Picture",
                    "ord": 2,
                    "rtl": false,
                    "size": 20,
                    "sticky": false
                },
                {
                    "font": "Arial",
                    "media": [],
                    "name": "Mnemonic",
                    "ord": 3,
                    "rtl": false,
                    "size": 20,
                    "sticky": false
                }
            ],
            "latexPost": "\\end{document}",
            "latexPre": "\\documentclass[12pt]{article}\n\\special{papersize=3in,5in}\n\\usepackage[utf8]{inputenc}\n\\usepackage{amssymb,amsmath}\n\\pagestyle{empty}\n\\setlength{\\parindent}{0in}\n\\begin{document}\n",
            "latexsvg": false,
            "name": "Basic-f18ab",
            "req": [
                [
                    0,
                    "any",
                    [
                        0
                    ]
                ]
            ],
            "sortf": 0,
            "tags": [],
            "tmpls": [
                {
                    "afmt": "{{FrontSide}}\n\n<hr id=answer>\n\n{{Back}}\n\n\n{{Big Picture}}\n\n{{#Tags}}\n<div id=\"tags-container\">{{Tags}}</div>\n<script>\nvar tagContainer = document.getElementById(\"tags-container\")\nif (tagContainer.childElementCount == 0) {\n var tagList= tagContainer.innerHTML.split(\" \");\n var kbdList = [];\n var newTagContent = document.createElement(\"div\");\n\n for (var i = 0; i < tagList.length;  i++) {\n  var newTag = document.createElement(\"kbd\");\n  newTag.innerHTML = tagList[i];\n  newTagContent.append(newTag)\n }\n tagContainer.innerHTML = newTagContent.innerHTML;\n tagContainer.style.cursor = \"default\";\n}\n</script>\n{{/Tags}}",
                    "bafmt": "",
                    "bfont": "",
                    "bqfmt": "",
                    "bsize": 0,
                    "did": null,
                    "name": "Card 1",
                    "ord": 0,
                    "qfmt": "{{Front}}"
                }
            ],
            "type": 0,
            "vers": []
        }
    ],
    "notes": [
        {
            "__type__": "Note",
            "fields": [
                "Differentiate the mutations that lead to cancers",
                "mutations genes that lead to defects in:<br>-growth proliferation pathways, apoptosis, or cell cycle\ncheckpoints.&nbsp; These mutations can include:<br>-mutations<br>-major chromosomal rearrangements involving chromosomal\ntranslocations, <br>-duplications<br>&nbsp;-Dysregulation of normal epigenetics-→disruption of oncogenes and tumor-suppressor genes",
                "SLO 1",
                ""
            ],
            "guid": "A>4zD(>Qj%",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Describe the process of inheritance and disease\nprogression in familiar cancers<br>SLO 2",
                "Example: breast and ovarian cancer mutation of BRCA2 C3590G allele<br>Autosomal dominant inheritance?",
                "",
                ""
            ],
            "guid": "s!E6jL5hq;",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "What is the 2 hit model of cancer genetics?<br>SLO 3",
                "Tumor-suppressor genes require two\nloss-of-function mutations to disrupt their role in the regulation of cell\ngrowth and proliferation. <br>-Double mutations seen in inherited cancers<br>-Many follow an autosomal dominance pattern due to the high\nincidence of cancer in the family<br>-Loss of heterozygosity common i.e. normal copy of tumor suppressor is lost&nbsp;",
                "",
                ""
            ],
            "guid": "G]w&gV#[_l",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Etiology and inheritance pattern of Multiple Endocrine Adenomatosis Type 2/MEN2<br>SLO 4",
                "cause: activation of RET oncogene which activates tyroskine kinase-→activation of MEN2 leads to growth in autonomic ganglia/kidneys-→<br>-GOF mutation-→development of MEN2-→possibility of developing medullary carcinoma of\nthe thyroid and/or neuromas.&nbsp;",
                "",
                ""
            ],
            "guid": "b5U&^Yrq_U",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Etiology of retinoblastoma?<br>SLO 4",
                "<b>Inherited form</b><br>-1 mutation in Rb is inherited<br>-second mutation is sporadic-→loss of all Rb and development of cancer (2 hit model)<br>-multiple tumors, bilateral eyes, early onset<br>-not all w/inherited Rb allele will develop cancer, approx 40%<br><b>Sporadic form</b><br>-2 sporadic Rb mutations, neither mutation inherited.<b> will affect eye unilaterally, later onset in life, single tumors</b>",
                "",
                ""
            ],
            "guid": "A[SRGulU&X",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Etiology of Li Fraunemi syndrome?<br>SLO 4",
                "<b>Cause:</b> inherited mutation in the gene encoding <b>p53</b>.&nbsp;2 hit model required<br><b>Symptoms: </b>diverse subset of potential cancers is\nexpected.&nbsp;<br>onset in childhood or early adulthood<br>-linked to high incidence of breast cancers, osteosarcomas, other soft-tissue sarcomas,<br>-There is also a link to other cancers such as\nneuromas, leukemias and adrenocortical carcinomas",
                "",
                ""
            ],
            "guid": "n%U#mDVN2t",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "<div>Familial adenomatous polyposis-etiology, symptoms, treatment<br>SLO 4</div>",
                "<b>Etiology: </b>mutation in tumor suppressor APC, which is involved in the degradation of beta-catenin\nin the absence of Wnt signaling<br><b>Symptoms</b>: cancer in colon and rectum. Benign tumor growth (polyps) develop by teenage\nyears.&nbsp;&nbsp;<br><b>Treatment:</b> remove colon; thousands of polyps can possibly develop",
                "",
                ""
            ],
            "guid": "E-|k9(4/x#",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "<div>Familial breast and ovarian cancer-etiology and symptoms<br>SLO 4</div>",
                "<b>Etiology: </b>BRCA 1 and 2 mutations, which repair dsDNA breaks, facilitate tumor suppression and genome\nintegrity.&nbsp;<br><b>Symptoms:</b> linked to prostate cancer, 50-80% chance of developing breast cancer in women<br><br>",
                "",
                ""
            ],
            "guid": "mgY1Dy+PiK",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "<div>Describe how chromosomal translocation can lead to Burkitt's lymphoma<br>SLO 5</div>",
                "<b>Burkitt's Lymphoma:&nbsp;</b>&nbsp;The\ntranslocation involving chromosomes 8 and 14 transfers the coding region for <b>Myc</b>\nto the region on chromosome 14 containing the immunoglobulin heavy chain.&nbsp; <br>- transfers the promoter\nfrom the immunoglobulin heavy chain to the Myc oncogene, increasing Myc\nexpression and activating growth and proliferation.&nbsp;<br>",
                "",
                ""
            ],
            "guid": "QS]79s#TLE",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Describe how chromosomal translocation can lead to CML<br>SLO 5",
                "<div>-<b>sporadic </b>(not hereditary) cancer<br>-translocation between chromosomes 9 (ABL gene) and 22 (BCR gene), in the middle of a\ngene encoding region.&nbsp; <br>-The new chromosome 22 (with portion of chromosome\n9) encodes a new chimeric protein=Philadelphia\nchromosome. <br>-The new chimeric protein is part BCR (gene of unknown function and\nhalf ABL - tyrosine kinase). <b>BCR-ABL</b> contains the tyrosine kinase\nactivity of the original ABL, <b>but with increased activity leading to increased\ncell growth.&nbsp;</b></div>",
                "",
                ""
            ],
            "guid": "b{D?)dV9aD",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Describe how drugs have been designed to\nspecifically treat cancer based on the molecular aspect of the mutation\n(imatinib).<br>SLO 6&nbsp;",
                "<div>For treatment of CML caused by the\nPhiladelphia chromosome and the BCR-ABL oncogene, (<b>imatinib</b>)&nbsp; inhibits BCR-ABL, but not the normal ABL tyrosine\nkinase.&nbsp; This specific design was able to\nreduce the side effects seen in broadly affecting chemotherapeutics and\nallowing treatment with higher doses of the inhibitor.&nbsp;</div>",
                "",
                ""
            ],
            "guid": "yB>doQDBMc",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "Describe how drugs have been designed to\nspecifically treat cancer based on the molecular aspect of the mutation\n(EGF receptor)<br>SLO 6",
                "<div>non-small cell lung cancer: gene for the <b>EGF receptor</b> is activated.&nbsp; By inhibiting that specific mutation or\nreceptor, the side effects seen with broader scale, cytotoxic chemotherapeutics\ncan be avoided. </div>\n<div>&nbsp;</div>",
                "",
                ""
            ],
            "guid": "nRPFls[0R3",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        },
        {
            "__type__": "Note",
            "fields": [
                "<div>Describe how gene expression profiling is used\nin the treatment of cancer&nbsp;<br>SLO 7</div>",
                "<div>-examining the mRNA levels in various tumors-→discover which genes are commonly upregulated (gain-of-function) or\ndownregulated (loss-of-function) in the tumor type.&nbsp; <br>&nbsp;-data is&nbsp; sorted based on\ntumor types (determined by pathology/ histology) and mRNA level into\nclusters.&nbsp; -clustering is examined to find correlating genes (expression signatures) that are found in\nsimilar tumors. -The application of these gene signatures for tumors aid in\ndetermining drug therapies, prognosis, management approach, and potential\ntreatment targets. </div>\n<div>&nbsp;</div>",
                "<img src=\"paste-06b2914e3c5d990893caa4f38632125072211bab.jpg\"><br><img src=\"paste-69274b465dcda3b05d6ecd4bfb8afc1be486f880.jpg\"><br><div>Expression patterns for a series of genes (along the vertical\naxis at&nbsp;&nbsp;<i>left&nbsp;&nbsp;</i>) for series\nof patient tumors, with the tumors arranged along the horizontal axis\nat&nbsp;&nbsp;<i>top&nbsp;&nbsp;</i>so that\ntumors with more similar expression patterns are grouped more closely together.\nThe tumors appear to generally cluster into two groups, which are then\ncorrelated with long-term survival.</div><br>",
                ""
            ],
            "guid": "KRGsnpwpjO",
            "note_model_uuid": "67fe187c-79b1-11ec-a1eb-f45c899656dd",
            "tags": [
                "**MSBS::MBM2::Block1::Week3"
            ]
        }
    ]
}